Literature DB >> 31915289

The Clinical and Laboratory Standards Institute Subcommittee on Antimicrobial Susceptibility Testing: Background, Organization, Functions, and Processes.

Melvin P Weinstein1, James S Lewis2.   

Abstract

The Clinical and Laboratory Standards Institute (CLSI) Subcommittee on Antimicrobial Susceptibility Testing (AST SC) is a volunteer-led, multidisciplinary consensus body that develops and publishes standards and guidelines (among other products) for antimicrobial susceptibility testing (AST) methods and results interpretation in the United States and internationally. The Subcommittee (SC) meets face-to-face twice yearly, and its working groups (WGs) are active throughout the year via teleconferences. All meetings are open to the public. Participants include clinical microbiologists, infectious disease (ID) pharmacists, and infectious disease physicians representing the health care professions, government, and industry. Individuals who work for a company with a primary financial dependency on drug sales cannot serve as voting members, and well-defined conflict of interest polices are in place. In addition to developing and updating susceptibility breakpoints, the SC develops and validates new testing methods, provides guidance on how results should be interpreted and applied, sets quality control ranges, and educates users through seminars, symposia, and webinars. Based on its work, the SC publishes print and electronic standards and guidelines, including an annual update, the Performance Standards for Antimicrobial Susceptibility Testing (M100). This commentary will describe the background, organization, functions, and operational processes of the AST SC.
Copyright © 2020 American Society for Microbiology.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31915289      PMCID: PMC7041576          DOI: 10.1128/JCM.01864-19

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  3 in total

1.  Point-Counterpoint: Differences between the European Committee on Antimicrobial Susceptibility Testing and Clinical and Laboratory Standards Institute Recommendations for Reporting Antimicrobial Susceptibility Results.

Authors:  Gunnar Kahlmeter; Christian G Giske; Thomas J Kirn; Susan E Sharp
Journal:  J Clin Microbiol       Date:  2019-08-26       Impact factor: 5.948

Review 2.  Understanding and Addressing CLSI Breakpoint Revisions: a Primer for Clinical Laboratories.

Authors:  Romney M Humphries; April N Abbott; Janet A Hindler
Journal:  J Clin Microbiol       Date:  2019-05-24       Impact factor: 5.948

3.  Effects of various test media on the activities of 21 antimicrobial agents against Haemophilus influenzae.

Authors:  Michael R Jacobs; Saralee Bajaksouzian; Anne Windau; Peter C Appelbaum; Gengrong Lin; David Felmingham; Christine Dencer; Laura Koeth; Mendel E Singer; Caryn E Good
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

  3 in total
  30 in total

Review 1.  Overview of Changes to the Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing, M100, 31st Edition.

Authors:  Romney Humphries; April M Bobenchik; Janet A Hindler; Audrey N Schuetz
Journal:  J Clin Microbiol       Date:  2021-09-22       Impact factor: 5.948

2.  Mercaptopurine-Loaded Sandwiched Tri-Layered Composed of Electrospun Polycaprolactone/Poly(Methyl Methacrylate) Nanofibrous Scaffolds as Anticancer Carrier with Antimicrobial and Antibiotic Features: Sandwich Configuration Nanofibers, Release Study and in vitro Bioevaluation Tests.

Authors:  Samar A Salim; Elbadawy A Kamoun; Stephen Evans; Shahira H El-Moslamy; Esmail M El-Fakharany; Mohamed M Elmazar; A F Abdel-Aziz; R H Abou-Saleh; Taher A Salaheldin
Journal:  Int J Nanomedicine       Date:  2021-10-11

3.  A Chimeric Penicillin Binding Protein 2X Significantly Decreases in Vitro Beta-Lactam Susceptibility and Increases in Vivo Fitness of Streptococcus pyogenes.

Authors:  Randall J Olsen; Luchang Zhu; Regan E Mangham; Ahmad Faili; Samer Kayal; Stephen B Beres; James M Musser
Journal:  Am J Pathol       Date:  2022-07-15       Impact factor: 5.770

Review 4.  Clinical challenges treating Stenotrophomonas maltophilia infections: an update.

Authors:  Maria F Mojica; Romney Humphries; John J Lipuma; Amy J Mathers; Gauri G Rao; Samuel A Shelburne; Derrick E Fouts; David Van Duin; Robert A Bonomo
Journal:  JAC Antimicrob Resist       Date:  2022-05-05

5.  Longitudinal Analysis of Risk Factors for Clinical Outcomes of Enterobacteriaceae Meningitis/Encephalitis in Post-Neurosurgical Patients: A Comparative Cohort Study During 2014-2019.

Authors:  Yi-Jun Shi; Guang-Hui Zheng; Ling-Ye Qian; Rasha Alsamani Qsman; Guo-Ge Li; Guo-Jun Zhang
Journal:  Infect Drug Resist       Date:  2020-07-06       Impact factor: 4.003

6.  Acetate Activates Lactobacillus Bacteriocin Synthesis by Controlling Quorum Sensing.

Authors:  Fanqiang Meng; Haizhen Zhao; Ting Nie; Fengxia Lu; Chong Zhang; Yingjian Lu; Zhaoxin Lu
Journal:  Appl Environ Microbiol       Date:  2021-06-11       Impact factor: 4.792

7.  The Link between Occurrence of Class I Integron and Acquired Aminoglycoside Resistance in Clinical MRSA Isolates.

Authors:  Ahmed M El-Baz; Galal Yahya; Basem Mansour; Mohamed M A El-Sokkary; Reem Alshaman; Abdullah Alattar; Amira M El-Ganiny
Journal:  Antibiotics (Basel)       Date:  2021-04-23

8.  Reinvestigation of the structure-activity relationships of isoniazid.

Authors:  Pooja Hegde; Helena I M Boshoff; Yudi Rusman; Wassihun Wedajo Aragaw; Christine E Salomon; Thomas Dick; Courtney C Aldrich
Journal:  Tuberculosis (Edinb)       Date:  2021-06-05       Impact factor: 2.973

9.  Evaluation the effect of ZnO nanoparticle derived Bacillus subtilis on the expression of efflux pump genes (AdeB AdeRS) in Acinetobacter baumannii.

Authors:  Fatemeh Saleh; Farnaz Kheirandish; Farzaneh Hosseini; Fatemeh Yazdian
Journal:  J Environ Health Sci Eng       Date:  2021-05-26

10.  In vitro and in vivo toxicity and antibacterial efficacy of melittin against clinical extensively drug-resistant bacteria.

Authors:  Parvin Askari; Mohammad Hasan Namaei; Kiarash Ghazvini; Mehran Hosseini
Journal:  BMC Pharmacol Toxicol       Date:  2021-07-14       Impact factor: 2.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.